GO:0003860 3-hydroxyisobutyryl-CoA hydrolase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0003860 defines the enzymatic activity that hydrolyzes 3-hydroxy-2-methylpropanoyl-CoA (3-hydroxyisobutyryl-CoA) to CoA and 3-hydroxy-2-methylpropanoate, a critical step in valine catabolism.
• The enzyme 3-hydroxyisobutyryl-CoA hydrolase (HIBCH) is a member of the crotonase superfamily and catalyzes the reaction via an anhydride intermediate.
• HIBCH deficiency, caused by mutations in the HIBCH gene, leads to progressive infantile neurodegeneration and Leigh-like disease [4,7].
• Tissue distribution studies in canine tissues show that HIBCH activity is highest in liver and kidney, reflecting the importance of valine catabolism in these organs.
• In Sinorhizobium meliloti, a putative HIBCH is required for efficient symbiotic nitrogen fixation, indicating a broader biological role beyond mammals.
• Research on HIBCH includes enzyme assays, genetic knockout models, and clinical studies of patients with HIBCH deficiency [2,4,7].
Description
3-hydroxyisobutyryl-CoA hydrolase activity (GO:0003860) is a molecular function that catalyzes the hydrolysis of 3-hydroxy-2-methylpropanoyl-CoA to coenzyme A and 3-hydroxy-2-methylpropanoate. This reaction is a key step in the catabolism of the branched-chain amino acid valine, and the enzyme responsible, HIBCH, is highly conserved across species [5,6]. The activity was first purified and characterized from rat liver, where it was shown to be distinct from other valine catabolic enzymes. Since then, HIBCH has been identified in multiple organisms, including bacteria, where it plays a role in symbiotic nitrogen fixation. In humans, mutations in the HIBCH gene cause a severe neurometabolic disorder characterized by progressive neurodegeneration and Leigh-like disease [4,7]. Understanding the molecular mechanism, regulation, and disease relevance of this enzyme is therefore important for both basic biochemistry and clinical research.
3-hydroxyisobutyryl-CoA hydrolase activity At A Glance
| GO ID | GO:0003860 |
|---|---|
| GO term | 3-hydroxyisobutyryl-CoA hydrolase activity |
| Ontology | molecular_function |
| Synonym | 3-hydroxy-2-methylpropanoyl-CoA hydrolase activity; 3-hydroxy-isobutyryl CoA hydrolase activity; HIB CoA deacylase activity |
| Major function | Catalyzes the hydrolysis of 3-hydroxy-2-methylpropanoyl-CoA to CoA and 3-hydroxy-2-methylpropanoate |
| Reaction | 3-hydroxy-2-methylpropanoyl-CoA + H2O = CoA + 3-hydroxy-2-methylpropanoate |
| Enzyme class | Hydrolase (EC 3.1.2.-) |
| Subcellular location | Mitochondrial matrix (in eukaryotes) |
| Pathway | Valine catabolism |
What Is GO:0003860?
According to the Gene Ontology, GO:0003860 (3-hydroxyisobutyryl-CoA hydrolase activity) is defined as the catalysis of the reaction: 3-hydroxy-2-methylpropanoyl-CoA + H2O = CoA + 3-hydroxy-2-methylpropanoate. In simpler terms, it is an enzymatic activity that removes coenzyme A from 3-hydroxyisobutyryl-CoA by hydrolysis, releasing free coenzyme A and 3-hydroxyisobutyrate. This activity is synonymous with 3-hydroxy-2-methylpropanoyl-CoA hydrolase, 3-hydroxy-isobutyryl CoA hydrolase, and HIB CoA deacylase. The enzyme belongs to the crotonase superfamily and uses a unique mechanism involving an anhydride intermediate.
Why Is 3-hydroxyisobutyryl-CoA hydrolase activity Important in Cell Biology?
3-hydroxyisobutyryl-CoA hydrolase activity is essential for the proper catabolism of valine, and its dysfunction leads to the accumulation of toxic metabolites that cause severe neurological damage. The enzyme is also important in biotechnology and agriculture, as it is required for efficient symbiotic nitrogen fixation in certain rhizobia. In medicine, HIBCH deficiency is a rare but devastating disorder, and understanding the enzyme's mechanism can aid in diagnosis and potential therapies [2,4,7]. Moreover, the unique catalytic mechanism of HIBCH, involving an anhydride intermediate, makes it a model for studying divergent evolution within the crotonase superfamily.
• HIBCH deficiency causes progressive infantile neurodegeneration and Leigh-like disease [4,7].
• The enzyme is a key step in valine catabolism, and its activity is highest in liver and kidney.
• Mutations in HIBCH lead to accumulation of toxic metabolites, including methacrylyl-CoA, which can cause oxidative stress.
• HIBCH is required for efficient symbiotic nitrogen fixation in Sinorhizobium meliloti.
• The enzyme uses a unique anhydride intermediate mechanism, providing insights into enzyme evolution.
• HIBCH activity can be measured in tissue homogenates and cultured cells, aiding in diagnosis [5,6].
• Therapeutic strategies, such as exercise regimens, have been proposed for HIBCH deficiency.
• HIBCH is a potential target for gene therapy and small-molecule chaperones [4,7].
• Understanding HIBCH regulation may reveal links to metabolic disorders and cancer.
• HIBCH serves as a model for studying mitochondrial matrix hydrolases.
Molecular Mechanism of 3-hydroxyisobutyryl-CoA hydrolase activity
Substrate recognition and binding
In simple terms: The enzyme grabs its target molecule, 3-hydroxyisobutyryl-CoA, and positions it for a chemical reaction.
HIBCH specifically binds 3-hydroxy-2-methylpropanoyl-CoA (3-hydroxyisobutyryl-CoA) through interactions with the CoA moiety and the hydroxyl group of the substrate. The enzyme belongs to the crotonase superfamily, which typically binds CoA esters, and structural studies suggest that the active site accommodates the branched-chain substrate. The binding is thought to involve hydrogen bonding and hydrophobic interactions that stabilize the substrate in a conformation suitable for catalysis.
Catalytic mechanism and anhydride intermediate
In simple terms: The enzyme uses a special trick: it forms a temporary bond with part of the substrate to help break it down.
Unlike typical hydrolases, HIBCH catalyzes the hydrolysis of 3-hydroxyisobutyryl-CoA via an anhydride intermediate. The reaction proceeds by nucleophilic attack of an active-site residue (likely glutamate or aspartate) on the substrate, forming a covalent anhydride intermediate, which is then hydrolyzed by water to release the product. This mechanism is unusual among crotonase superfamily members and highlights the divergent evolution of this enzyme family.
Cofactors and metal requirements
In simple terms: The enzyme does not need any metal helpers; it works on its own.
HIBCH does not require metal ions or cofactors for its hydrolytic activity. The reaction is driven solely by the enzyme's active-site residues and water. This is consistent with its classification as a hydrolase and distinguishes it from other valine catabolic enzymes that require NAD+ or other cofactors [5,6].
Regulation of enzyme activity
In simple terms: The enzyme's activity can be turned up or down depending on the cell's needs.
The regulation of HIBCH activity is not fully understood, but tissue distribution studies in dogs show that activity is highest in liver and kidney, suggesting tissue-specific regulation. In humans, HIBCH expression may be regulated by metabolic demands, and mutations that reduce activity lead to disease [4,7]. There is no evidence for allosteric regulation or post-translational modifications, but further research is needed.
Key Genes Involved in GO:0003860 3-hydroxyisobutyryl-CoA hydrolase activity
The following genes and proteins are directly associated with 3-hydroxyisobutyryl-CoA hydrolase activity or its biological context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HIBCH | Encodes the enzyme 3-hydroxyisobutyryl-CoA hydrolase | Mutations cause HIBCH deficiency; target for gene therapy [4,7] |
| BCKDHA | Branched-chain alpha-keto acid dehydrogenase E1 alpha subunit | Upstream of HIBCH in valine catabolism; mutations cause maple syrup urine disease |
| BCKDHB | Branched-chain alpha-keto acid dehydrogenase E1 beta subunit | Upstream of HIBCH; related to branched-chain amino acid metabolism |
| DBT | Dihydrolipoamide branched chain transacylase E2 | Component of BCKD complex; upstream of HIBCH |
| DLD | Dihydrolipoamide dehydrogenase | Component of BCKD complex; upstream of HIBCH |
| HADHA | Hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha | Involved in fatty acid oxidation and possibly interacts with HIBCH |
| HADHB | Hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta | Mitochondrial enzyme; potential cross-talk with HIBCH |
| ACADM | Medium-chain acyl-CoA dehydrogenase | Fatty acid oxidation; may influence mitochondrial acyl-CoA pools |
| SLC25A20 | Carnitine-acylcarnitine translocase | Mitochondrial transporter; affects substrate availability |
| PCCA | Propionyl-CoA carboxylase alpha subunit | Related to branched-chain amino acid catabolism |
| PCCB | Propionyl-CoA carboxylase beta subunit | Related to branched-chain amino acid catabolism |
| MUT | Methylmalonyl-CoA mutase | Downstream of valine catabolism; related to metabolic disorders |
| MMAA | Methylmalonic aciduria type A protein | Involved in vitamin B12 metabolism; related to valine catabolism |
| MMAB | Methylmalonic aciduria type B protein | Involved in vitamin B12 metabolism |
| SLC22A5 | Organic cation/carnitine transporter 2 | Affects carnitine levels and mitochondrial metabolism |
| ETFA | Electron transfer flavoprotein alpha subunit | Mitochondrial electron transfer; related to fatty acid oxidation |
| ETFB | Electron transfer flavoprotein beta subunit | Mitochondrial electron transfer |
| ETFDH | Electron transfer flavoprotein dehydrogenase | Mitochondrial electron transfer |
How Is 3-hydroxyisobutyryl-CoA hydrolase activity Regulated?
The regulation of 3-hydroxyisobutyryl-CoA hydrolase activity is not well characterized. Tissue distribution studies in dogs indicate that enzyme activity is highest in liver and kidney, suggesting tissue-specific expression or regulation. In humans, HIBCH mRNA and protein levels may be regulated by metabolic state, but no specific transcription factors or signaling pathways have been definitively linked. The enzyme's activity is likely modulated by substrate availability and product inhibition, but further research is needed to elucidate these mechanisms.
3-hydroxyisobutyryl-CoA hydrolase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HIBCH | HIBCH deficiency (Leigh-like disease, neurodegeneration) | Hibch knockout mouse; patient-derived fibroblasts [4,7] |
| HIBCH | Exercise-induced dystonia | Hibch knockout mouse; exercise challenge studies |
| HIBCH | Symbiotic nitrogen fixation | Sinorhizobium meliloti deletion mutant; plant infection assays |
| HIBCH | Valine catabolism disorders | Patient-derived cell lines; enzyme activity assays [5,6] |
| HIBCH | Mitochondrial dysfunction | CRISPR knockout in HEK293 cells; Seahorse analysis |
HIBCH deficiency and Leigh-like disease
Mutations in the HIBCH gene cause 3-hydroxyisobutyryl-CoA hydrolase deficiency, an autosomal recessive disorder characterized by progressive infantile neurodegeneration, Leigh-like lesions, and ketoacidosis [4,7]. Patients typically present with developmental regression, hypotonia, and elevated metabolites such as 3-hydroxyisobutyrate. The disease is rare but severe, and diagnosis is confirmed by genetic testing and enzyme assays [4,7].
Therapeutic approaches for HIBCH deficiency
Management of HIBCH deficiency is primarily supportive, but a recent study reported a therapeutic regimen involving exercise for a patient with exercise-induced dystonia, which improved symptoms. This suggests that physical activity may modulate metabolic flux through the valine catabolic pathway. Other potential therapies include dietary restriction of valine and gene therapy, though these are experimental [4,7].
HIBCH in symbiotic nitrogen fixation
In the bacterium Sinorhizobium meliloti, a putative HIBCH is required for efficient symbiotic nitrogen fixation with legume plants. This finding highlights the evolutionary conservation of the enzyme and its importance beyond mammalian metabolism. It also suggests potential agricultural applications, such as engineering rhizobia for improved nitrogen fixation.
From 3-hydroxyisobutyryl-CoA hydrolase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of HIBCH loss on valine catabolism? | HIBCH knockout cell line (e.g., HEK293, HepG2) |
| How does a specific patient mutation affect enzyme activity? | Point mutation knock-in (e.g., HIBCH c.1298A>C) in cell lines |
| Can wild-type HIBCH rescue the phenotype? | Knock-in of tagged HIBCH (e.g., FLAG-HIBCH) for rescue experiments |
| What is the tissue-specific role of HIBCH? | Tissue-specific knockout mouse (e.g., liver-specific) |
| Does overexpression of HIBCH alter metabolic flux? | Overexpression of HIBCH in cell lines or mouse models |
| What proteins interact with HIBCH? | Tagged knock-in (e.g., HA-HIBCH) for immunoprecipitation |
How to Study the 3-hydroxyisobutyryl-CoA hydrolase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzyme activity assay | Hydrolysis of 3-hydroxyisobutyryl-CoA | Diagnosis of HIBCH deficiency |
| Western blot | HIBCH protein levels | Validation of knockout or overexpression |
| RT-qPCR | HIBCH mRNA expression | Tissue distribution studies |
| CRISPR knockout | Loss of HIBCH function | Modeling HIBCH deficiency |
| Metabolomics | Levels of valine catabolic intermediates | Patient diagnosis and flux analysis |
| Structural biology | 3D structure of HIBCH | Mechanistic studies |
| Immunoprecipitation | Protein-protein interactions | Identifying HIBCH binding partners |
| Next-generation sequencing | Mutations in HIBCH gene | Genetic diagnosis |
Enzyme activity assays
HIBCH activity can be measured in tissue homogenates or cell lysates using spectrophotometric or radiometric assays that monitor the hydrolysis of 3-hydroxyisobutyryl-CoA. These assays are essential for diagnosing HIBCH deficiency and for studying enzyme kinetics [5,6].
Genetic and genomic approaches
CRISPR-Cas9 knockout of HIBCH in cell lines or animal models allows researchers to study the consequences of loss of function. Point mutations can be introduced to model patient-specific variants. Overexpression studies can elucidate the effects of increased enzyme levels [4,7].
Metabolomics and flux analysis
Metabolomic profiling of patient samples or model systems can reveal accumulation of 3-hydroxyisobutyrate and other valine catabolic intermediates. Stable isotope tracing can measure flux through the pathway [4,7].
Structural biology
X-ray crystallography and cryo-EM can provide insights into the structure of HIBCH and its catalytic mechanism, including the anhydride intermediate. These studies inform drug design and mechanistic understanding.
How CRISPR Can Be Used to Study GO:0003860 3-hydroxyisobutyryl-CoA hydrolase activity
Knockout
CRISPR-Cas9 knockout of HIBCH in cell lines (e.g., HEK293, HeLa) or animal models (e.g., mouse) can recapitulate the metabolic block seen in HIBCH deficiency. These models are useful for studying the accumulation of toxic metabolites and for testing therapeutic interventions [4,7].
Point Mutation
Introducing patient-specific point mutations (e.g., c.1298A>C) into the HIBCH gene using CRISPR-Cas9 and homology-directed repair allows researchers to study the functional impact of these variants. This approach can reveal genotype-phenotype correlations and aid in diagnostic interpretation.
Knock-in
Knock-in of tagged HIBCH (e.g., FLAG or HA tag) enables affinity purification and interaction studies. It also allows for tracking the enzyme's subcellular localization and dynamics. Knock-in of wild-type HIBCH can rescue knockout phenotypes.
Overexpression
Overexpression of HIBCH in cell lines or transgenic animals can be achieved by CRISPR activation (CRISPRa) or by lentiviral transduction. This is useful for studying the effects of increased enzyme activity on valine catabolism and mitochondrial function.
How EDITGENE Supports 3-hydroxyisobutyryl-CoA hydrolase activity Research
Researchers studying 3-hydroxyisobutyryl-CoA hydrolase activity-related genes often need to determine whether a candidate gene is causally involved in a metabolic pathway or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell and animal models, enabling functional validation of genes like HIBCH and its regulators.
Contact EDITGENE today to design your custom CRISPR model for 3-hydroxyisobutyryl-CoA hydrolase activity research.
Frequently Asked Questions About 3-hydroxyisobutyryl-CoA hydrolase activity
What is 3-hydroxyisobutyryl-CoA hydrolase activity?
It is an enzymatic activity (GO:0003860) that catalyzes the hydrolysis of 3-hydroxy-2-methylpropanoyl-CoA to coenzyme A and 3-hydroxy-2-methylpropanoate, a step in valine catabolism.
What genes are involved in 3-hydroxyisobutyryl-CoA hydrolase activity?
The primary gene is HIBCH, which encodes the enzyme. Other genes in the valine catabolic pathway include BCKDHA, BCKDHB, DBT, and DLD [1,4].
What diseases are associated with HIBCH mutations?
Mutations in HIBCH cause HIBCH deficiency, a progressive infantile neurodegeneration with Leigh-like disease and ketoacidosis [4,7].
How is HIBCH deficiency diagnosed?
Diagnosis involves genetic testing for HIBCH mutations, enzyme activity assays in fibroblasts or liver tissue, and metabolomic profiling showing elevated 3-hydroxyisobutyrate [4,7].
What is the mechanism of HIBCH catalysis?
HIBCH catalyzes hydrolysis via an anhydride intermediate, a unique mechanism among crotonase superfamily enzymes.
Is HIBCH found in all organisms?
HIBCH is conserved from bacteria to humans. In Sinorhizobium meliloti, it is required for symbiotic nitrogen fixation.
What are the symptoms of HIBCH deficiency?
Symptoms include developmental regression, hypotonia, seizures, and ketoacidosis, often triggered by illness or stress [4,7].
Can HIBCH deficiency be treated?
Treatment is supportive; a recent case report suggests exercise may improve exercise-induced dystonia. Dietary valine restriction is sometimes used.
What model systems are used to study HIBCH?
Models include HIBCH knockout mice, patient-derived fibroblasts, and CRISPR-edited cell lines [4,7].
How can I study HIBCH using CRISPR?
EDITGENE offers knockout, point mutation, knock-in, and overexpression services for HIBCH and related genes, as well as library screening and bioinformatics support.
Conclusion
3-hydroxyisobutyryl-CoA hydrolase activity (GO:0003860) is a critical enzymatic function in valine catabolism, with profound implications for human health and microbial symbiosis. The enzyme HIBCH, which carries out this activity, is linked to severe neurological disease when mutated, and its unique catalytic mechanism has attracted interest from biochemists. Continued research using CRISPR-based models and advanced metabolomics will further illuminate its regulation and therapeutic potential.
References
- 1. Adam MP et al.. 1993. Nuclear Gene-Encoded Leigh Syndrome Spectrum Overview.. PMID: 26425749
- 2. Xu Y et al.. 2019. A therapeutic regimen for 3-hydroxyisobutyryl-CoA hydrolase deficiency with exercise-induced dystonia.. Eur J Paediatr Neurol 23(5):755-759 PMID: 31679561
- 3. Zamani M et al.. 2017. A putative 3-hydroxyisobutyryl-CoA hydrolase is required for efficient symbiotic nitrogen fixation in Sinorhizobium meliloti and Sinorhizobium fredii NGR234.. Environ Microbiol 19(1):218-236 PMID: 27727485
- 4. Loupatty FJ et al.. 2007. Mutations in the gene encoding 3-hydroxyisobutyryl-CoA hydrolase results in progressive infantile neurodegeneration.. Am J Hum Genet 80(1):195-9 PMID: 17160907
- 5. Shimomura Y et al.. 1994. Purification and partial characterization of 3-hydroxyisobutyryl-coenzyme A hydrolase of rat liver.. J Biol Chem 269(19):14248-53 PMID: 8188708
- 6. Ooiwa T et al.. 1995. Regulation of valine catabolism in canine tissues: tissue distributions of branched-chain aminotransferase and 2-oxo acid dehydrogenase complex, methacrylyl-CoA hydratase and 3-hydroxyisobutyryl-CoA hydrolase.. Biochim Biophys Acta 1243(2):216-20 PMID: 7873565
- 7. Yamada K et al.. 2014. Clinical and biochemical characterization of 3-hydroxyisobutyryl-CoA hydrolase (HIBCH) deficiency that causes Leigh-like disease and ketoacidosis.. Mol Genet Metab Rep 1:455-460 PMID: 27896122
- 8. Wong BJ et al.. 2003. Divergent function in the crotonase superfamily: an anhydride intermediate in the reaction catalyzed by 3-hydroxyisobutyryl-CoA hydrolase.. J Am Chem Soc 125(40):12076-7 PMID: 14518977
